These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 24388859)

  • 1. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats.
    Gorain B; Choudhury H; Kundu A; Sarkar L; Karmakar S; Jaisankar P; Pal TK
    Colloids Surf B Biointerfaces; 2014 Mar; 115():286-94. PubMed ID: 24388859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview.
    Brunner HR
    J Hum Hypertens; 2002 May; 16 Suppl 2():S13-6. PubMed ID: 11967728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative biodistribution and safety profiling of olmesartan medoxomil oil-in-water oral nanoemulsion.
    Gorain B; Choudhury H; Tekade RK; Karan S; Jaisankar P; Pal TK
    Regul Toxicol Pharmacol; 2016 Dec; 82():20-31. PubMed ID: 27815174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
    Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
    Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform.
    Choudhury H; Gorain B; Karmakar S; Biswas E; Dey G; Barik R; Mandal M; Pal TK
    Int J Pharm; 2014 Jan; 460(1-2):131-43. PubMed ID: 24239580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes.
    Pugsley MK
    Proc West Pharmacol Soc; 2005; 48():35-8. PubMed ID: 16416656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced bioavailability and antihypertensive activity of nisoldipine loaded nanoemulsion: optimization, cytotoxicity and uptake across Caco-2 cell line, pharmacokinetic and pharmacodynamic studies.
    Mundada VP; Patel MH; Mundada PK; Sawant KK
    Drug Dev Ind Pharm; 2020 Mar; 46(3):376-387. PubMed ID: 32031412
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic profiles of a fixed-dose combination of olmesartan medoxomil and amlodipine in healthy Chinese males and females.
    Chen X; Hu P; Jiang J; Liu T; Zhong W; Liu H; Zhao Q
    Clin Drug Investig; 2012 Dec; 32(12):783-90. PubMed ID: 23160920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oil based nanocarrier for improved oral delivery of silymarin: In vitro and in vivo studies.
    Parveen R; Baboota S; Ali J; Ahuja A; Vasudev SS; Ahmad S
    Int J Pharm; 2011 Jul; 413(1-2):245-53. PubMed ID: 21549187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of olmesartan medoxomil in the rat monocrotaline model of pulmonary hypertension.
    Kato T; Nasu T; Sonoda H; Ito KM; Ikeda M; Ito K
    J Cardiovasc Pharmacol; 2008 Jan; 51(1):18-23. PubMed ID: 18209564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism.
    Gao F; Zhang Z; Bu H; Huang Y; Gao Z; Shen J; Zhao C; Li Y
    J Control Release; 2011 Jan; 149(2):168-74. PubMed ID: 20951749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a population pharmacokinetic model to describe olmesartan medoxomil/ hydrochlorothiazide (20/12.5 mg) FDC tablet in male healthy South Korean subjects.
    Chae JW; Baek IH; Seo JW; Jung SH; Back HM; Song BJ; Lee BY; Yun HY; Kang W; Kwon KI
    Int J Clin Pharmacol Ther; 2014 Aug; 52(8):676-83. PubMed ID: 24849193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?
    Wehling M
    Clin Ther; 2004; 26 Suppl A():A21-7. PubMed ID: 15291376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olmesartan/amlodipine: blood pressure lowering and beyond in special populations.
    Erdine S
    Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):31-44. PubMed ID: 22222315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update.
    Chrysant SG; Dimas B; Shiraz M
    J Hum Hypertens; 2007 Sep; 21(9):699-708. PubMed ID: 17554345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and bioavailability assessment of ramipril nanoemulsion formulation.
    Shafiq S; Shakeel F; Talegaonkar S; Ahmad FJ; Khar RK; Ali M
    Eur J Pharm Biopharm; 2007 May; 66(2):227-43. PubMed ID: 17127045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
    Gardner SF; Franks AM
    Ann Pharmacother; 2003 Jan; 37(1):99-105. PubMed ID: 12503943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system.
    Kang MJ; Kim HS; Jeon HS; Park JH; Lee BS; Ahn BK; Moon KY; Choi YW
    Drug Dev Ind Pharm; 2012 May; 38(5):587-96. PubMed ID: 21988221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.
    Rosenbaum D; Girerd X
    Curr Med Res Opin; 2012 Feb; 28(2):179-86. PubMed ID: 22114906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.